Inhibition of P53/miR-34a improves diabetic endothelial dysfunction via activation of SIRT1

Area of Science:

• Cardiovascular Biology
• Endocrinology
• Molecular Medicine

Background:

• Endothelial dysfunction is a key factor in diabetic macrovascular complications and mortality.
• The tumor suppressor protein P53 plays a pathogenic role in endothelial dysfunction.
• Investigating P53 inhibition offers a potential therapeutic strategy for diabetic vascular disease.

Purpose of the Study:

• To investigate the effect of P53 inhibition on high glucose-induced endothelial dysfunction.
• To elucidate the molecular pathway involving P53, microRNA-34a (miR-34a), and sirtuin 1 (SIRT1) in diabetic endothelial dysfunction.

Main Methods:

• Utilized high glucose (HG)-treated endothelial cells (ECs) and streptozotocin-induced diabetic mouse models.
• Administered P53 inhibitors (pifithrin-α, P53-siRNA), miR-34a inhibitor (miR-34a-I), and SIRT1 inhibitors (EX-527, Sirt1-siRNA).
• Assessed endothelial inflammation, oxidative stress, P53 acetylation, miR-34a levels, and SIRT1 protein expression.

Main Results:

• P53 inhibition (PFT-α, P53-siRNA) attenuated HG-induced endothelial inflammation and oxidative stress.
• P53 inhibition decreased P53 acetylation and miR-34a levels, increasing SIRT1 protein.
• Both PFT-α and miR-34a-I protected against endothelial dysfunction in vitro and in vivo, a process dependent on SIRT1 and regulated by miR-34a.

Conclusions:

• A novel P53/miR-34a/SIRT1 pathway is identified as crucial in mediating diabetic endothelial dysfunction.
• Inhibition of P53 and miR-34a demonstrates therapeutic potential for managing diabetic macrovascular complications.
• Targeting this pathway presents a promising strategy for treating diabetic cardiovascular disease.